Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Anti-programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study.
Panhaleux M, Espitia O, Terrier B, Manson G, Maria A, Humbert S, Godbert B, Perrin J, Achille A, Arrondeau J, Kostine M, Fallet V, Pugnet G, Chaigne B, Champiat S, Laparra A, Danlos FX, Launay D, Penel N, Lambotte O, Michot JM, Forestier A. Panhaleux M, et al. Among authors: arrondeau j. Eur J Cancer. 2022 Jan;160:134-139. doi: 10.1016/j.ejca.2021.10.018. Epub 2021 Nov 19. Eur J Cancer. 2022. PMID: 34810048 Clinical Trial.
[Immunotherapies and targeted therapies in medical oncology].
Rousseau B, Champiat S, Loirat D, Arrondeau J, Lemoine N, Soria JC. Rousseau B, et al. Among authors: arrondeau j. Bull Cancer. 2014 Jan 1;101(1):31-9. doi: 10.1684/bdc.2013.1865. Bull Cancer. 2014. PMID: 24333964 Review. French.
Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Franck N, Arrondeau J, Guégan S, Mansuet-Lupo A, Alexandre J, Damotte D, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: arrondeau j. Invest New Drugs. 2017 Dec;35(6):842-847. doi: 10.1007/s10637-017-0476-6. Epub 2017 May 31. Invest New Drugs. 2017. PMID: 28569347
The impact of body composition parameters on severe toxicity of nivolumab.
Hirsch L, Bellesoeur A, Boudou-Rouquette P, Arrondeau J, Thomas-Schoemann A, Kirchgesner J, Gervais C, Jouinot A, Chapron J, Giraud F, Wislez M, Alexandre J, Blanchet B, Goldwasser F. Hirsch L, et al. Among authors: arrondeau j. Eur J Cancer. 2020 Jan;124:170-177. doi: 10.1016/j.ejca.2019.11.003. Epub 2019 Nov 30. Eur J Cancer. 2020. PMID: 31794927
Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer.
Fournel L, Boudou-Rouquette P, Prieto M, Hervochon R, Guinet C, Arrondeau J, Alexandre J, Damotte D, Wislez M, Batteux F, Icard P, Goldwasser F, Alifano M. Fournel L, et al. Among authors: arrondeau j. Cancer Chemother Pharmacol. 2020 Oct;86(4):497-505. doi: 10.1007/s00280-020-04142-9. Epub 2020 Sep 16. Cancer Chemother Pharmacol. 2020. PMID: 32936316
Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T, Puszkiel A, Cardoso E, Balakirouchenane D, Narjoz C, Arrondeau J, Fallet V, Khoudour N, Guidi M, Vidal M, Declèves X, Csajka C, Alexandre J, Cadranel J, Fabre E, Wislez M, Goldwasser F, Blanchet B. Rodier T, et al. Among authors: arrondeau j. Pharmaceutics. 2022 Sep 1;14(9):1844. doi: 10.3390/pharmaceutics14091844. Pharmaceutics. 2022. PMID: 36145591 Free PMC article.
Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients.
Heidelberger V, Goldwasser F, Kramkimel N, Jouinot A, Huillard O, Boudou-Rouquette P, Chanal J, Arrondeau J, Franck N, Alexandre J, Blanchet B, Leroy K, Avril MF, Dupin N, Aractingi S. Heidelberger V, et al. Among authors: arrondeau j. Invest New Drugs. 2017 Aug;35(4):436-441. doi: 10.1007/s10637-017-0464-x. Epub 2017 Apr 10. Invest New Drugs. 2017. PMID: 28396974
Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, Halpin R, Creasy T, Bantsimba-Malanda C, Arrondeau J, Goldwasser F, Boudou-Rouquette P, Fournel L, Roche N, Burgel PR, Goc J, Devi-Marulkar P, Germain C, Dieu-Nosjean MC, Cremer I, Herbst R, Damotte D. Biton J, et al. Among authors: arrondeau j. Am J Respir Crit Care Med. 2018 Oct 1;198(7):928-940. doi: 10.1164/rccm.201706-1110OC. Am J Respir Crit Care Med. 2018. PMID: 29518341
TP53, STK11, and EGFR Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma.
Biton J, Mansuet-Lupo A, Pécuchet N, Alifano M, Ouakrim H, Arrondeau J, Boudou-Rouquette P, Goldwasser F, Leroy K, Goc J, Wislez M, Germain C, Laurent-Puig P, Dieu-Nosjean MC, Cremer I, Herbst R, Blons H, Damotte D. Biton J, et al. Among authors: arrondeau j. Clin Cancer Res. 2018 Nov 15;24(22):5710-5723. doi: 10.1158/1078-0432.CCR-18-0163. Epub 2018 May 15. Clin Cancer Res. 2018. PMID: 29764856
61 results